Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs

Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs

Source: 
Xconomy
snippet: 

Sophisticated computational tools have guided Relay Therapeutics in its efforts to develop new drugs based on analysis of the movement and shape of disease-causing proteins.